Physician profile
Rohit Gupta
NPI 1386641496
$9,810.13
in general payments reported to CMS, 2019-2025
34 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $1,314 · 2021: $3,622 · 2022: $1,011 · 2023: $1,043 · 2024: $886 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974 · Education: $20.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.04 |
| Education | $20.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $4,530.06 | 2019-2023 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals Lp | $849.98 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $585.02 | 2022-2025 | Tarpeyo |
| Amgen INC. | $473.41 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $372.79 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $356.89 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $335.25 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $280.00 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $261.85 | 2019-2025 | Jynarque, Voyxact |
| Bard Peripheral Vascular, INC. | $218.23 | 2020-2023 | Pristine |
| Glaxosmithkline, LLC. | $214.81 | 2021-2024 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $165.74 | 2022-2025 | |
| Medtronic, INC. | $152.24 | 2023 | Micra |
| Alexion Pharmaceuticals, INC. | $128.49 | 2019-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $104.22 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $100.00 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $99.04 | 2019-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $98.85 | 2019 | |
| Novo Nordisk INC | $78.70 | 2024-2025 | Ozempic |
| Portola Pharmaceuticals, LLC | $58.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $44.67 | 2019 | |
| Scpharmaceuticals INC. | $42.63 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.02 | 2022-2024 | Gattex |
| Lilly USA, LLC | $33.59 | 2023-2024 | Jardiance |
| Baxter Healthcare | $27.04 | 2024 | Renal - Acute |
| Kyowa Kirin, INC. | $19.90 | 2022 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Genentech USA, INC. | $15.98 | 2019 | |
| Ani Pharmaceuticals, INC. | $14.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.21 | 2022 | |
| Shield Therapeutics INC | $13.28 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $11.43 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.